Introduction: This manuscript offers an in-depth comparative examination of the effectiveness of higher-dose (double standard-dose and high-dose) influenza vaccines in contrast to a single standard-dose vaccine when it comes to alleviating major cardiovascular events.
Study Design: Meta-Analysis.
Methods: To conduct this study, an exhaustive search was carried out in the medical English literature using databases such as PubMed/MEDLINE, EMBASE, and the Cochrane CENTRAL until 10 April 2024. The evaluation of associations was achieved through the calculation of pooled relative risks (RRs) accompanied by their corresponding 95% confidence intervals (CIs).
Results: A meticulous analysis encompassed a comprehensive cohort of 68,713 patients. Among these participants, 34,430 individuals were randomly assigned to receive a higher-dose influenza vaccination, whereas 34,283 received the standard influenza vaccination. Contrary to initial expectations, a higher-dose influenza vaccine did not manifest elevated efficacy compared to the standard-dose vaccine in terms of mitigating major cardiovascular events. The computed pooled RR stood at 1.0, accompanied by a 95% CI ranging from 0.93 to 1.10.
Conclusion: While this systematic review and meta-analysis did not find a statistically significant advantage of higher-dose influenza vaccines over a single standard-dose vaccine in preventing major cardiovascular events, the observed trend towards risk reduction warrants continued investigation. These findings contribute to the ongoing dialogue surrounding vaccination strategies and their implications for cardiovascular outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.puhe.2024.06.034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved Population.
JAMA Cardiol
January 2025
Division of General Medicine, Columbia University Irving Medical Center, New York, New York.
Importance: The Southern Community Cohort Study (SCCS) Polypill Trial showed that a cardiovascular polypill (a single pill containing a statin and 3 half-standard dose antihypertensive medications) effectively controls cardiovascular disease (CVD) risk factors in a majority Black race and low-income population. The cost-effectiveness of polypill treatment in this population has not been previously studied.
Objective: To determine the cost-effectiveness of the cardiovascular polypill.
Recurrent Hypophosphatemia Following a Single Dose of Parenteral Iron Administration.
Cureus
November 2024
Acute Medicine, Royal Stoke University Hospital, Stoke-on-Trent, GBR.
Although parenteral iron is widely used to treat iron deficiency anemia (IDA), some side effects have been inadequately explored. Hypophosphatemia is becoming a well-documented, yet poorly understood, side effect of parenteral iron infusion, oftentimes causing serious and/or prolonged complications. In this article, we discuss the case of a 33-year-old female with IDA who suffered debilitating physical and mental symptoms of significant recurrent hypophosphatemia following a single standard dose of parenteral iron administration.
View Article and Find Full Text PDFLive attenuated goatpox vaccination in pregnant Murcia-Granada goats: dosage implications and outcomes.
BMC Vet Res
December 2024
Animal Pathology Department, Instituto Agroalimentario de Aragón-IA2 (Universidad de Zaragoza-CITA), Veterinary Faculty of Zaragoza, C/Miguel Servet 177, Zaragoza, 50013, Spain.
Background: Infectious diseases, particularly the Goatpox virus (GTPV) from the Poxviridae family, significantly impact livestock health and agricultural economies, especially in developing regions. Recent GTPV outbreaks in previously eradicated areas underscore the need for effective control measures, with vaccination being the most reliable strategy. This study investigates the effects of administering standard and double doses of live attenuated goatpox vaccine in pregnant Murcia-Granada goats, a non-native breed in Iran, to determine optimal vaccination protocols.
View Article and Find Full Text PDFThe association between baseline IgE level and urticaria control at six months of omalizumab treatment in chronic urticaria.
Eur Ann Allergy Clin Immunol
November 2024
Division of Allergy and Clinical Immunology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
There is limited data on the use of baseline IgE level as a predictor of omalizumab response in chronic urticaria (CU). The aim of the present study was to determine if baseline serum total IgE level is associated with response at six months of standard-dose omalizumab. The study was designed as a retrospective, single-center, cohort survey.
View Article and Find Full Text PDFIbrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B-Cell Lymphoma.
Hematol Oncol
November 2024
Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Ramat Gan, Israel.
Article Synopsis
- A phase II clinical study evaluated the effectiveness of a treatment combo (ibrutinib, bendamustine, and rituximab) in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after stem cell transplants or in elderly patients.
- The study showed a 49.1% overall response rate among patients who received at least one cycle, with better outcomes for those with relapsed disease (72.3%) versus refractory disease (37.8%).
- Patients experiencing complete or partial responses had significantly longer median overall survival of 28.1 months, while common side effects included fatigue, diarrhea, and nausea, indicating that the treatment is both safe and effective for those needing potential transplantation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!